Philips Receives Frost & Sullivan's 2025 Global Enabling Technology Leadership Recognition for Excellence in Digital Pathology-Healthcare Informatics

Philips (NYSE:PHG) received Frost & Sullivan's 2025 Global Enabling Technology Leadership Recognition for Digital Pathology–Healthcare Informatics on Jan 29, 2026.

Rhea-AI Summary

Philips (NYSE:PHG) received Frost & Sullivan's 2025 Global Enabling Technology Leadership Recognition for Digital Pathology–Healthcare Informatics on Jan 29, 2026.

The award cites Philips' integrated digital pathology portfolio, FDA 510(k) clearance for primary diagnosis, >3,500 pathologists across 40+ countries, and >38 million slides scanned globally.

Positive

• Holds FDA 510(k) clearance for primary digital pathology diagnosis
• Installed base of 3,500+ pathologists across 40+ countries
• 38 million slides scanned globally, indicating scale and clinical validation
• Recognition by Frost & Sullivan for strategy and execution enhances market positioning

Negative

• Ibex AI labeled Research Use Only (RUO) in the U.S., limiting clinical deployment
• Certain cloud features rely on third-party AWS claims that may not apply in all markets

Argus Jan 29 session

+0.79% close to close Open Argus

Details

News Market Reaction – PHG

In the Jan 29 session, PHG gained 0.79%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights external validation of Philips’ digital pathology and healthcare inform...

Analysis

This announcement highlights external validation of Philips’ digital pathology and healthcare informatics ecosystem, reinforcing its long-term innovation story seen in prior recognitions and AI-focused acquisitions. With more than 3,500 pathologists using its platform and over 38 million slides scanned, scale and clinical adoption are key takeaways. In evaluating this news, investors might track how such endorsements support commercial traction, product differentiation, and future updates to Philips’ 2026 outlook and strategic execution.

Key Figures

Current price: $29.02 52-week range: $20.606 – $30.30 Annual R&D investment: EUR 1.7 billion +5 more

Current price

$29.02

As of pre-news market context

52-week range

$20.606 – $30.30

52-week low and high for PHG

Annual R&D investment

EUR 1.7 billion

Clarivate innovator recognition summary, about 9% of sales

R&D as % of sales

9%

Clarivate innovator recognition summary

Installed MRI systems

2,000+ installations

Helium-free MRI magnet technology footprint

Helium saved

≈6 million liters

Impact of helium-free MRI magnet technology

Digital pathology users

3,500+ pathologists

Pathologists using Philips’ digital pathology platform across 40+ countries

Slides scanned

38 million+ slides

Global volume on Philips’ digital pathology platform

Historical Context

5 past events · Latest: Jan 21

5 events

1. Jan 21

   Innovation recognition

   24h Move

   +2.5%

   Named a Clarivate Top 100 Global Innovator for the 13th straight year.

2. Jan 14

   Business separation

   24h Move

   +1.6%

   Launch of Heartstream as independent emergency care company under Philips license.

3. Jan 14

   Business divestiture

   24h Move

   +1.6%

   Emergency Care Holdings acquires Philips Emergency Care business, creating Heartstream platform.

4. Dec 15

   AI imaging acquisition

   24h Move

   -0.6%

   Agreement to acquire SpectraWAVE to enhance coronary intravascular imaging portfolio.

5. Dec 04

   Outlook reiteration

   24h Move

   -4.9%

   Reaffirmed timing and expectations for 2026 outlook with anticipated growth and margin expansion.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

digital pathology, healthcare informatics, FDA 510(k) clearance, software development kit (SDK)

4 terms

digital pathology medical

"recognition in the Digital Pathology–Healthcare Informatics sector for its outstanding"

Digital pathology is the process of converting traditional microscope slides into high-resolution digital images and using software, cloud systems, and sometimes AI to view, analyze, store and share those images. It matters to investors because it can speed diagnosis, enable remote consultations, reduce laboratory bottlenecks and create software-driven services and recurring revenue—like the shift from film to digital photography, unlocking scale, efficiency and new monetization opportunities in healthcare.

healthcare informatics medical

"Digital Pathology–Healthcare Informatics sector for its outstanding achievements"

Healthcare informatics is the use of digital tools, data and software to collect, organize and analyze medical information so caregivers can make better decisions and run systems more efficiently. For investors it matters because improvements are like upgrading a city’s traffic control — they can lower costs, speed services, reduce errors, create new product or subscription revenue, and affect how quickly hospitals or clinics adopt a company’s technology, all of which influence profitability and growth.

FDA 510(k) clearance regulatory

"IntelliSite Pathology Solution, the first digital pathology platform to receive FDA 510(k) clearance"

FDA 510(k) clearance is an official approval from the U.S. Food and Drug Administration that allows medical devices to be legally sold in the United States. It indicates the device is considered safe and effective based on its similarity to already approved products. For investors, achieving 510(k) clearance can signal a company's readiness to bring a medical device to market and generate revenue.

software development kit (SDK) technical

"PIPS enables iSyntax files and with the Software Development Kit (SDK) third-party"

A software development kit (SDK) is a bundled set of tools, code samples and templates that helps programmers build apps or add features to a platform, like giving builders a box of prefabricated parts and instructions. For investors, an SDK matters because it speeds product development, encourages third parties to build on a company’s platform, and can expand a company’s user base or recurring revenues—factors that affect growth, competitive advantage and valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Philips is recognized for its market-leading innovation and comprehensive digital pathology ecosystem, driving global transformation in diagnostics and healthcare informatics

SAN ANTONIO, Jan. 29, 2026 /PRNewswire/ -- Frost & Sullivan is pleased to announce that Philips has been awarded the 2025 Global Enabling Technology Leadership Recognition in the Digital Pathology–Healthcare Informatics sector for its outstanding achievements in delivering next-generation digital pathology innovation, accelerated workflow modernization, and clinical informatics. This recognition highlights Philips Healthcare's consistent leadership in driving measurable outcomes, strengthening its global market presence, and delivering customer-centric innovation in an increasingly complex healthcare environment.

Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: strategy effectiveness and strategy execution. Philips Healthcare excels in both, demonstrating an ability to align long-term innovation strategy with global market demand while executing at scale with consistency and precision. "Philips leads the global healthcare industry in patent applications. This propensity for innovation has positioned the company at the forefront of one of the sector's fastest-growing fields: digital pathology. Building on this legacy, Philips Healthcare has emerged as a global leader in digital pathology," said Melissa Kenig, Senior Consultant at Frost & Sullivan.

Guided by a long-term growth strategy centered on digital innovation, customer partnerships, and scalable enterprise informatics, Philips has demonstrated a strong ability to adapt and lead in a rapidly evolving diagnostic ecosystem. The company's sustained investments in digital pathology and AI-enabled^1,2 informatics have enabled it to deliver value across diverse clinical environments, from large academic medical centers to multi-site laboratory networks.

Innovation remains foundational to Philips Healthcare's approach. Its integrated digital pathology portfolio, including high-performance slide scanners, a robust image management system, advanced AI-powered² workflows, cloud archiving by Cloud Data Services³, and full-lab workflow support, addresses the end-to-end needs of modern pathology practices. These capabilities are strengthened by the Philips IntelliSite Pathology Solution, the first digital pathology platform to receive FDA 510(k) clearance for primary diagnosis.

"As diagnostic demand grows and resources tighten, digital pathology is becoming foundational to modern care. Frost & Sullivan's recognition underscores our commitment to turning innovation into meaningful impact by streamlining workflows, enabling collaboration, and accelerating diagnosis, while responsibly advancing AI to support better patient care," said Martijn Hartjes, Business Unit Leader Clinical Informatics at Philips.

Philips' commitment to customer experience further amplifies its global leadership. With more than 3,500 pathologists across over 40 countries leveraging Philips' digital pathology platform, and over 38 million slides scanned globally, the company has built one of the largest, most clinically validated installed bases in the industry. Its structured implementation services, extensive training programs, and globally unified support organization ensure strong customer engagement, high system uptime, and seamless scalability across enterprise networks.

Frost & Sullivan commends Philips for setting the industry benchmark in competitive strategy, technology innovation, and global execution. Philips's vision for open, interoperable, and AI-powered² digital diagnostics is shaping the future of digital pathology and redefining what is possible for healthcare organizations seeking to improve diagnostic accuracy, speed, and collaboration at scale.

Each year, Frost & Sullivan presents the Enabling Technology Leadership Recognition to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market share, customer satisfaction, and competitive positioning. The recognition honors organizations that are transforming their industries through forward-thinking innovation and growth excellence.

1 PIPS enables iSyntax files and with the Software Development Kit (SDK) third-party companies can use this for AI capabilities. 2 With Ibex AI, Ibex AI is Research Use Only (RUO) in the U.S. 3 With our partner AWS. Third party claims from AWS, which may not apply in all markets and may be updated from time to time. The functionalities and benefits of the solution depend on customer-specific configuration and use. Please contact your local Philips representative for (market) availability.

Frost & Sullivan Best Practices Recognition

Frost & Sullivan's Best Practices Recognitions honor companies across regional and global markets that exhibit exceptional achievement and consistent excellence in areas such as leadership, technological innovation, customer experience, and strategic product development. Each recognition is the result of a rigorous analytical process in which Frost & Sullivan industry experts benchmark performance through comprehensive interviews, deep-dive analysis, and extensive secondary research. The goal is to identify true best-in-class organizations that are driving transformative growth and setting new industry standards.
Contact us: Start the discussion.

Contact:
Ashley Shreve
E: ashley.weinkauf@frost.com

About Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips' patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,300 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

View original content:https://www.prnewswire.com/news-releases/philips-receives-frost--sullivans-2025-global-enabling-technology-leadership-recognition-for-excellence-in-digital-pathologyhealthcare-informatics-302674221.html

SOURCE Frost & Sullivan

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What recognition did Philips (PHG) receive on January 29, 2026?

Philips received Frost & Sullivan's 2025 Global Enabling Technology Leadership Recognition for digital pathology. According to Philips, the award acknowledges its innovation, strategy execution, and enterprise-scale digital pathology deployments.

Does Philips' digital pathology platform have FDA clearance and what does that mean for PHG shareholders?

Yes — Philips' IntelliSite Pathology Solution holds FDA 510(k) clearance for primary diagnosis. According to Philips, this clearance supports clinical adoption and validates the platform's use in diagnostic workflows across regulated markets.

How extensive is Philips' installed base for digital pathology as reported on Jan 29, 2026?

Philips reports more than 3,500 pathologists in over 40 countries and over 38 million slides scanned. According to Philips, these metrics reflect a large, clinically validated global installed base.

Are there limitations to Philips' AI capabilities mentioned in the recognition for PHG?

Some AI offerings have deployment limits; for example, Ibex AI is Research Use Only in the U.S. According to Philips, functionality and availability depend on regional approvals and customer-specific configuration.

Why did Frost & Sullivan award Philips in digital pathology and what aspects were highlighted for PHG?

Frost & Sullivan cited Philips' strategy effectiveness, execution at scale, and integrated digital pathology ecosystem. According to Philips, key highlights include AI-enabled informatics, slide scanning scale, and global customer support infrastructure.